6 days ago · See the latest status of our innovative investigational therapies and pipeline as well as read stories, explore our company, and connect with us.

Mitsubishi Tanabe Pharma Corporation is a Japanese pharmaceuticals company from Osaka, [1] a subsidiary of Mitsubishi Chemical Holdings Corporation. Mitsubishi Pharma Corporation (三菱ウェルファーマ株式会社, Mitsubishi Werufāma Kabushiki-gaisha) was formed in 2001 from the merger of Mitsubishi-Tokyo Pharmaceuticals and Welfide Corporation. On October 1, 2007, Tanabe Seiyaku Co ...

Mitsubishi Tanabe Pharma America, Inc. Mitsubishi Tanabe Pharma Canada, Inc. MP Healthcare Venture Management, Inc. Mitsubishi Tanabe Pharma Europe Ltd. Mitsubishi Tanabe Pharma GmbH; NeuroDerm Ltd. Taiwan Tanabe Seiyaku Co., Ltd. Mitsubishi Tanabe Pharma Korea Co., Ltd. PT Mitsubishi Tanabe Pharma Indonesia

3 days ago · Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about ¥510 ...

5 days ago · Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry. ...

4 days ago · Bain is laying out 510 billion Japanese yen ($3.3 billion) to acquire Tanabe Pharma in a carve-out transaction from its parent Mitsubishi Chemical Group, the investment firm said Friday.

4 days ago · Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical ...

4 days ago · Bain buys 340-year-old pharma company to fast-track Japan’s drug development Private equity firm expects $3.3bn acquisition of Tanabe will get boost from eased approval process for new medicine

Dec 27, 2024 · Mitsubishi Tanabe Pharma and Daiichi Sankyo to Expand Strategic Alliance in the Diabetes Field The companies enter into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, following co-operation for TENELIA ® Tablets, a selective DPP-4 inhibitor, and CANAGLU ® Tablets, an SGLT2 ...

For more than 300 years, our parent company, Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, has proudly pursued medical advances; we’ve discovered and produced several first in class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM) and amyotrophic lateral sclerosis (ALS).